What Are Anabolic Steroids? A Complete Medical Guide

MEDICAL DISCLAIMER: This article is intended for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.

Introduction

Anabolic steroids are among the most widely recognized and widely misunderstood substances in both medicine and popular culture. The word “steroid” triggers vastly different reactions depending on context: for a physician, it may describe a life-saving medication for a patient with muscle-wasting disease; for a sports fan, it conjures images of disgraced athletes and scandal; for a public health worker, it represents a growing concern among younger populations. Understanding what anabolic steroids actually are requires cutting through the noise and returning to the science.

In the most precise medical sense, anabolic steroids, more formally known as anabolic-androgenic steroids, or AAS, are synthetic derivatives of the naturally occurring male sex hormone testosterone. They are called “anabolic” because they promote tissue building, particularly muscle, and “androgenic” because they drive the development of male physical characteristics. These two properties are fundamentally linked in all currently known steroid compounds, though researchers have long worked to develop agents that maximize anabolic effects while minimizing androgenic ones.

From a clinical standpoint, anabolic steroids occupy a legitimate and important position in the medical toolkit. Endocrinologists prescribe testosterone for men with hypogonadism, a condition where the body fails to produce adequate levels of the hormone. Oncologists use them to combat the muscle-wasting effects of cancer. Hematologists have historically prescribed certain steroids to stimulate red blood cell production in anemia patients. These are well-established, evidence-based applications, used under strict medical supervision with regular laboratory monitoring.

Yet anabolic steroids are also among the most widely misused substances in non-medical contexts. Estimates suggest that several million people worldwide use these compounds for non-medical purposes, primarily to enhance athletic performance or physical appearance. This non-medical use, particularly at doses far exceeding those used therapeutically, is associated with a wide spectrum of serious and sometimes irreversible health consequences. The cardiovascular, hormonal, psychological, and hepatic effects of supraphysiologic steroid use are extensively documented in peer-reviewed medical literature.

This guide is designed to provide a thorough, evidence-based examination of anabolic steroids from every angle: their chemistry, their history, how they work, their legitimate medical applications, their documented risks and side effects, their legal status, and what treatment looks like for those experiencing dependence. Whether you are a healthcare professional seeking a refresher, a student researching the topic, a parent concerned about a child, or an individual who has encountered these substances in your own life, this article aims to give you accurate, useful, and complete information grounded in established medical science.

Understanding Steroids: The Basic Science

To understand anabolic steroids, it is helpful first to understand what steroids are as a chemical class. In chemistry, steroids are defined by their molecular structure: specifically, they share a characteristic arrangement of four carbon rings fused together, known as the gonane or sterane nucleus. This core carbon scaffold is the structural foundation for a vast family of biologically important compounds, including cholesterol, bile acids, sex hormones, adrenal hormones, and vitamin D.

The human body synthesizes multiple types of steroids naturally, all ultimately derived from cholesterol through a series of enzymatic transformations. The most familiar natural steroids include testosterone and estradiol (sex hormones), cortisol and aldosterone (adrenal hormones produced in the adrenal cortex), and progesterone (a reproductive hormone). Each of these natural steroids exerts specific biological effects by binding to particular receptor proteins inside cells and influencing gene expression.

Within this large family of steroidal compounds, anabolic-androgenic steroids represent a specific subgroup defined by two intersecting biological activities: anabolic effects, which promote the synthesis of macromolecules, especially proteins, leading to tissue growth; and androgenic effects, which drive the development and maintenance of male secondary sex characteristics such as facial hair, deepened voice, and muscle mass distribution. In practical terms, all known AAS compounds possess both activities to varying degrees, though the ratio differs between compounds.

It is important to distinguish clearly between anabolic-androgenic steroids and corticosteroids, another major class of clinically important steroidal drugs. Corticosteroids, including commonly prescribed medications such as prednisone, dexamethasone, and hydrocortisone, act on entirely different receptor systems and serve entirely different functions. They reduce inflammation and suppress immune activity, making them invaluable for conditions like asthma, rheumatoid arthritis, and autoimmune diseases. They do not promote muscle growth in the way AAS do, and they carry a different profile of side effects. Confusing the two is a common error in public discourse, but they are pharmacologically and clinically distinct drug classes.

Endogenous (naturally produced) testosterone is the reference point for all synthetic AAS. Produced primarily in the Leydig cells of the testes in men and in smaller amounts in the adrenal glands and ovaries in women, testosterone regulates a broad range of physiological functions: red blood cell production, bone mineral density, fat distribution, sexual function, mood regulation, and, critically, muscle protein synthesis. Synthetic AAS are engineered chemical modifications of the testosterone molecule, designed to extend its half-life, alter its ratio of anabolic to androgenic activity, or change its route of administration. These modifications give rise to the diverse pharmacological landscape of the AAS family.

A Brief History of Anabolic Steroids

The story of anabolic steroids begins in the early twentieth century, as physiologists began investigating the biological basis of masculine characteristics. Researchers had long observed that castration eliminated male physical traits and behavior, suggesting that the testes secreted some vital substance. In 1889, the French physiologist Charles-Edouard Brown-Sequard famously and controversially injected himself with extracts from the testicles of dogs and guinea pigs, reporting a remarkable rejuvenation of energy and physical capacity. His self-experimentation was largely dismissed, but it catalyzed decades of serious scientific inquiry into gonadal hormones.

The decisive breakthrough came in 1935, when three independent research teams nearly simultaneously isolated and characterized testosterone. Ernst Laqueur and his colleagues in the Netherlands isolated crystalline testosterone from bull testicular tissue. Working separately, Adolf Butenandt in Germany and Leopold Ruzicka in Switzerland synthesized it chemically, an achievement for which Butenandt and Ruzicka were awarded the Nobel Prize in Chemistry in 1939. Within a few years of testosterone’s isolation, chemists began producing synthetic analog molecules based on the testosterone scaffold but modified to be orally active or to have a prolonged duration of action.

Early therapeutic applications were explored during the late 1930s and through World War II. Some historical accounts suggest that Nazi physicians administered testosterone to soldiers to increase aggression and endurance, though this claim remains historically contested. More documented was the use of AAS to treat malnourished concentration camp survivors and wounded soldiers. In the late 1940s and early 1950s, physicians began prescribing testosterone for a range of conditions, including hypogonadism, osteoporosis, and the physical decline associated with aging.

The intersection of anabolic steroids and competitive sport began in the 1950s. Soviet athletes, particularly weightlifters, began using testosterone preparations with remarkable results at international competitions, including the 1952 Helsinki Olympics. John Ziegler, an American team physician who observed this advantage firsthand, worked with Ciba Pharmaceuticals to develop a more specifically anabolic compound, resulting in the creation of methandrostenolone, commercially sold as Dianabol, approved by the FDA in 1958. Dianabol rapidly spread through elite athletics and eventually permeated amateur sport, powerlifting, and bodybuilding communities.

As non-medical steroid use expanded dramatically through the 1970s and 1980s, health authorities and sports governing bodies moved to respond. The International Olympic Committee added anabolic steroids to its list of banned substances in 1976, and testing began at the Montreal Olympics the same year. In the United States, the Anabolic Steroid Control Act of 1990 classified AAS as Schedule III controlled substances under the Controlled Substances Act — a designation reflecting meaningful potential for physical and psychological dependence. The schedule was expanded by the Designer Anabolic Steroid Control Act of 2014 to cover newly synthesized compounds not previously specified in law.

How Anabolic Steroids Work in the Body

The primary mechanism by which anabolic steroids exert their effects involves binding to specific intracellular receptor proteins called androgen receptors (AR). Androgen receptors are members of the nuclear receptor superfamily transcription factors that regulate gene expression directly at the level of DNA. They are widely distributed throughout the body, with particularly high concentrations in skeletal muscle, bone, the prostate gland, skin, and the brain. When a steroidal molecule binds to an androgen receptor, it causes a conformational change in the receptor protein, which then travels to the cell nucleus and binds to specific DNA sequences called androgen response elements (AREs).

Once the activated androgen receptor-steroid complex binds to androgen response elements, it modulates the transcription of target genes — effectively switching certain genes on and off. In skeletal muscle, this process upregulates the expression of proteins involved in muscle fiber growth and repair, most importantly by increasing muscle protein synthesis. It also promotes nitrogen retention, meaning the body retains more dietary nitrogen (a marker of protein metabolism) rather than excreting it. Positive nitrogen balance is a reliable indicator of an anabolic state — the body is building more protein than it is breaking down.

Beyond direct androgen receptor activation, anabolic steroids influence muscle growth through effects on satellite cells. These specialized muscle stem cells lie dormant along muscle fibers and are activated in response to mechanical stress or hormonal signals. Testosterone and its analogs stimulate satellite cell activation, proliferation, and fusion with existing muscle fibers, increasing both the number of myonuclei within a muscle cell (an effect that may be long-lasting or permanent) and the cell’s capacity for protein synthesis. This satellite cell mechanism helps explain why steroid users can achieve hypertrophy beyond the theoretical ceiling of natural muscle growth.

Anabolic steroids also stimulate the production of erythropoietin (EPO) in the kidneys, which in turn drives the production of red blood cells in the bone marrow. More red blood cells mean greater oxygen-carrying capacity, which enhances endurance performance. This erythropoietic effect is clinically valuable in certain anemias but contributes to cardiovascular risk in non-medical use, as increased red cell mass thickens the blood and raises the risk of clots. Additionally, steroids interact with glucocorticoid receptors, partially blocking the catabolic (tissue-breaking) effects of cortisol, which reduces post-exercise muscle protein breakdown and accelerates recovery.

The androgenic effects of AAS stem from the same androgen receptor activation mechanism but occur in tissues where androgenic effects predominate over anabolic ones: the skin (stimulating sebaceous gland activity and contributing to acne), hair follicles (accelerating androgenic hair loss in genetically susceptible individuals), the prostate (stimulating growth), the larynx (deepening the voice), and the brain (influencing mood and behavior). The balance of anabolic versus androgenic activity varies between different AAS compounds and is a key parameter in both clinical prescribing and non-medical use decisions, though no compound on the market achieves purely anabolic effects without any androgenic activity.

Types and Classifications of Anabolic Steroids

Testosterone itself — in various esterified forms that alter its absorption rate and duration of action — is the most fundamental anabolic steroid and the one that has been most extensively studied in clinical settings. Common pharmaceutical forms include testosterone enanthate, testosterone cypionate, and testosterone undecanoate (an oral form with favorable pharmacokinetics). Short-acting esters such as testosterone propionate are used when rapid adjustment of dosage is needed. All synthetic AAS are ultimately derived from the testosterone scaffold through chemical modification of the carbon rings or side chains.

AAS can be broadly divided into oral and injectable forms, a distinction with significant clinical and toxicological implications. Injectable preparations are typically esterified — fatty acid chains are attached to the testosterone molecule, making it oil-soluble and slowing its release from the injection site. This gives injectable compounds longer half-lives ranging from a few days to several weeks. Oral AAS, on the other hand, have been chemically modified at the C-17 position of the steroid nucleus — a modification called 17-alpha alkylation — which prevents the liver from rapidly metabolizing them during “first-pass” digestion. While this makes them orally bioavailable, the 17-alpha alkyl group is responsible for the hepatotoxicity (liver toxicity) characteristic of oral AAS.

Among the best-known anabolic steroids, several deserve specific mention. Nandrolone (as nandrolone decanoate, sold as Deca-Durabolin) is a widely studied injectable AAS with a relatively favorable anabolic-to-androgenic ratio and is legitimately prescribed for anemia and osteoporosis in some countries. Stanozolol (Winstrol) is an oral compound known for its use in several high-profile doping scandals, including that of sprinter Ben Johnson at the 1988 Seoul Olympics. Oxandrolone (Anavar) is a mild oral steroid frequently prescribed for pediatric use and for muscle-wasting conditions due to its relatively low androgenic activity. Boldenone undecylenate (Equipoise), originally developed as a veterinary drug, has found its way into non-medical human use.

A critical distinction that affects both safety and efficacy is between pharmaceutical-grade steroids — products manufactured under regulatory oversight, with verified purity and dosage — and non-pharmaceutical-grade products acquired through illicit channels, commonly referred to as underground laboratory products. Research and analytical testing of illicitly obtained anabolic steroids have consistently found alarming rates of mislabeling, contamination, incorrect dosing, and the presence of entirely undisclosed substances, including diuretics, stimulants, and other hormones. This quality control issue represents a serious independent risk for anyone using non-prescribed AAS, entirely separate from the known pharmacological risks of the compounds themselves.

In recent decades, the AAS landscape has become considerably more complex with the emergence of designer steroids — synthetic compounds specifically engineered to evade detection by standard anti-doping tests while retaining anabolic activity. The BALCO scandal of 2003, which revealed the use of tetrahydrogestrinone (THG), a previously undetectable compound, among elite athletes, illustrated the sophisticated chemistry involved in this ongoing cat-and-mouse dynamic between athletes seeking performance enhancement and anti-doping authorities developing detection methods. Designer steroids generally lack any safety data because they have never been tested in formal clinical trials.

Legitimate Medical Uses of Anabolic Steroids

Anabolic steroids have several well-established, evidence-supported medical applications. The most common is the treatment of male hypogonadism, a clinical condition in which the testes fail to produce adequate testosterone. Hypogonadism can be primary (originating in the testes themselves, as in Klinefelter syndrome or testicular injury) or secondary (originating in the hypothalamic-pituitary axis, as occurs in hypopituitarism or after traumatic brain injury). Clinical guidelines from major endocrinology organizations support testosterone replacement therapy (TRT) for men with confirmed hypogonadism, defined by consistently low morning testosterone levels combined with characteristic symptoms such as decreased libido, fatigue, erectile dysfunction, loss of muscle mass, and depressive mood.

Delayed puberty in adolescent males is another recognized medical indication. When a teenage boy fails to show signs of pubic development by age 14, a condition called constitutional delay of growth and puberty, short courses of low-dose testosterone can be prescribed to initiate pubescent development and prevent the psychological distress associated with peer developmental lag. This use requires careful monitoring because premature closure of the epiphyseal growth plates, the cartilaginous areas at the ends of long bones that are responsible for longitudinal growth, is a real risk if testosterone is used at excessive doses or before the appropriate developmental stage.

Muscle wasting associated with chronic diseases represents another well-supported clinical application. HIV-associated wasting syndrome, in which patients experience progressive involuntary weight loss and muscle depletion, has been treated with AAS in randomized controlled trials showing significant improvements in lean body mass and quality of life. Similarly, the muscle wasting and cachexia associated with late-stage cancer, severe burns, and certain other critical illnesses can be partly addressed with anabolic steroid therapy as part of a broader nutritional and rehabilitative strategy, though this remains an area of ongoing clinical research.

In the field of hematology, certain anabolic steroids, particularly oxymetholone (Anadrol), were historically used to treat aplastic anemia, a condition in which the bone marrow fails to produce adequate blood cells. Steroids stimulate erythropoietin production and directly affect the bone marrow to increase red cell output. While recombinant erythropoietin (rHuEPO) has largely replaced AAS for renal anemia (anemia of chronic kidney disease), AAS retain a role in aplastic anemia management when other treatments fail, particularly in resource-limited settings. Some forms of anemia associated with myelodysplastic syndrome or bone marrow disorders may also respond to AAS therapy.

In more recent decades, the use of anabolic steroids in gender-affirming hormone therapy for transgender men (female-to-male individuals) has become an important and medically supported application. Testosterone therapy is a central component of masculinizing hormone treatment, promoting the development of secondary male sex characteristics, such as facial and body hair, clitoral enlargement, voice deepening, and increased muscle mass, while suppressing the menstrual cycle. This use is guided by established clinical protocols from organizations including the Endocrine Society and the World Professional Association for Transgender Health (WPATH), and it involves ongoing monitoring of hormone levels and cardiovascular parameters.

Non-Medical and Performance-Enhancing Use

Beyond their legitimate clinical roles, anabolic steroids are widely used for non-medical purposes — primarily to enhance athletic performance, accelerate muscle growth, and improve physical appearance. Non-medical AAS use is far more common than many estimates suggest. Survey data from multiple countries indicate that between 1% and 5% of adult males in Western nations report lifetime non-medical AAS use, with prevalence considerably higher among competitive bodybuilders and strength athletes. The practice is no longer confined to elite sport; the majority of current users are recreational gym-goers whose primary motivation is aesthetic rather than competitive.

Non-medical users employ several characteristic usage patterns that are markedly different from therapeutic prescribing. Cycling involves periods of AAS use (“on cycle”) interspersed with drug-free periods (“off cycle”) to allow the body’s natural hormone system to partially recover. Stacking refers to the concurrent use of two or more different AAS — often combining oral and injectable compounds — with the rationale of achieving synergistic effects or maintaining particular physiological parameters. Pyramiding describes the practice of gradually increasing doses at the start of a cycle, reaching a peak, and then tapering down toward the end. These patterns are based on gym lore and anecdotal experience rather than clinical evidence.

A defining characteristic of non-medical AAS use is the dramatic disparity in dosage compared with therapeutic use. Replacement doses of testosterone for hypogonadism are typically in the range of 75–200 milligrams per week, maintaining serum testosterone within the normal physiological range. In contrast, non-medical users commonly report weekly dosages of 500–1000 milligrams or more, sometimes exceeding therapeutic doses by a factor of five to twenty. Stacking protocols may involve the concurrent use of three or more compounds, creating complex pharmacological interactions that have never been systematically studied for safety. This dose escalation is a primary driver of the adverse health effects documented in the medical literature.

Routes of administration in non-medical use mirror those found in clinical settings, but with important differences in practice. Intramuscular injection remains the most common route, with users typically injecting into the gluteal, deltoid, or quadriceps muscles. Self-injection carries risks of infection, abscess formation, and nerve injury when performed without proper technique or sterile equipment. Oral forms are also widely used, particularly by beginners, due to the perceived convenience of not requiring injections. Transdermal gels and patches, originally developed for TRT, have also found their way into non-medical use, though their lower bioavailability makes them less popular among those seeking maximum performance effects.

Short-Term Physical Effects

The short-term physical effects of anabolic steroid use at supraphysiologic doses are, in part, why their non-medical use persists despite well-documented risks. The most prominent and sought-after effect is a significant increase in skeletal muscle mass. Well-controlled studies in healthy male volunteers have demonstrated gains of 3–7 kilograms of lean body mass over 10–12 week cycles, with even greater gains reported in longer or more heavily dosed protocols. This muscle hypertrophy is the result of the increased protein synthesis, satellite cell activation, and anti-catabolic mechanisms described earlier. Importantly, a portion of the weight gain reflects water retention caused by sodium and water retention linked to androgenic activity and aromatization of testosterone to estrogen.

Muscular strength increases substantially and disproportionately to the gains in muscle size alone, a phenomenon that reflects both the direct effects on muscle contractile proteins and central nervous system adaptations. Steroid users commonly report dramatic improvements in their one-repetition maximum on major lifts within the first few weeks of a cycle, often preceding visible changes in body composition. This rapid strength increase can paradoxically contribute to musculoskeletal injury, as tendons and ligaments — which adapt more slowly than muscles to training stimuli — may be unable to handle the sudden increase in load capacity, leading to tendon tears and strains.

Dermatological effects appear quickly and are frequently among the first noticeable side effects. Acne vulgaris — particularly of the back, shoulders, and chest — is common because androgens stimulate the sebaceous glands to produce more sebum. In users with a genetic predisposition, androgenic alopecia (pattern baldness) may be accelerated, as testosterone is converted in hair follicles to dihydrotestosterone (DHT), which miniaturizes follicles sensitive to this hormone. Oiliness of the skin and increased body odor due to apocrine gland stimulation are also frequently reported. These dermatological effects reverse partially or fully upon cessation of use.

Changes in mood, energy, and libido are commonly reported in the short term. Many users describe an initial phase of elevated mood, increased confidence, reduced fatigue, and heightened sexual desire — effects that contribute to the appeal of these compounds and to the development of psychological dependence. However, these euphoric or energized states can coexist with increased irritability, a shorter fuse, and periods of disproportionate anger — the basis of what is colloquially termed “roid rage,” though this phenomenon is more nuanced than popular culture suggests, as discussed in the section on psychological effects. Sleep architecture may also be disrupted, particularly with certain orally active compounds.

Cardiovascular Risks: What the Evidence Shows

Of all the organ systems affected by non-medical anabolic steroid use, the cardiovascular system is arguably the one most clearly and severely implicated in the medical literature. A substantial body of evidence — including retrospective cohort studies, echocardiographic imaging studies, post-mortem analyses, and prospective clinical investigations — documents a range of serious cardiovascular consequences associated with long-term supraphysiologic AAS use. The cardiovascular risks of AAS are now considered by cardiologists to represent the most significant long-term health threat of these compounds.

Left ventricular hypertrophy (LVH) — pathological enlargement of the heart’s main pumping chamber — is among the most consistently observed findings in long-term AAS users. While some degree of cardiac hypertrophy in endurance athletes represents a physiological adaptation (“athlete’s heart”), the hypertrophy induced by AAS is distinctly different in character: it involves concentric remodeling with increased wall thickness but reduced chamber compliance and impaired diastolic function. Multiple echocardiographic studies comparing AAS users to non-using athletes of similar training backgrounds have found significantly greater LV wall thickness and mass in AAS users, along with decreased LV fractional shortening and ejection fraction over time.

Anabolic steroids exert profoundly adverse effects on the blood lipid profile, which constitutes a significant independent cardiovascular risk factor. The most consistent finding is a substantial reduction in high-density lipoprotein cholesterol (HDL-C, the “good” cholesterol) — often by 50% or more with oral AAS — and an increase in low-density lipoprotein cholesterol (LDL-C, the “bad” cholesterol). This dyslipidemia creates an atherogenic lipid environment that promotes the formation of atherosclerotic plaques in the arterial walls. Epidemiological studies have found evidence of premature atherosclerosis, measured by carotid intima-media thickness, in long-term AAS users even in the absence of other traditional cardiovascular risk factors.

Thrombotic complications — including deep vein thrombosis, pulmonary embolism, and ischemic stroke — have been documented in AAS users, most likely reflecting the polycythemia (elevated red blood cell count and haematocrit) and alterations in platelet function and clotting factor concentrations induced by these drugs. Case reports and case series consistently describe myocardial infarction (heart attack) in young, otherwise healthy AAS users, a highly unusual clinical scenario that typically prompts investigation for underlying thrombotic or coronary spasm mechanisms. A 2017 study published in Circulation found that the mortality rate of male competitive powerlifters who had used AAS was significantly higher than that of matched non-using lifters, with cardiovascular causes predominating.

Liver Effects: Hepatotoxicity and Beyond

The liver is a primary site of steroid metabolism, and certain classes of AAS — specifically the 17-alpha alkylated oral steroids — impose significant hepatic stress. 17-alpha alkylation prevents first-pass hepatic metabolism by blocking the cytochrome P450 enzyme system from rapidly degrading the steroid molecule, but this modification simultaneously renders the compound hepatotoxic. Clinical manifestations of steroid-related hepatotoxicity range from asymptomatic elevation of liver enzymes (detected on routine blood tests) to clinically significant cholestasis, peliosis hepatis, and — in the most severe cases — hepatocellular carcinoma.

Cholestasis — impairment of bile flow — is the most common form of hepatotoxicity associated with oral AAS. Affected individuals may experience jaundice, dark urine, pruritus (itching), and elevated levels of conjugated bilirubin and alkaline phosphatase on laboratory testing. In most cases, cholestasis resolves within weeks to months of discontinuing the offending AAS, but severe or prolonged cases can progress to more lasting hepatic damage. Elevation of the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) is almost universal with regular oral AAS use and is routinely monitored in clinical settings as a hepatic safety marker.

Peliosis hepatis is a rare but serious condition — characterized by blood-filled cysts within the liver parenchyma — that has been associated with both therapeutic and non-therapeutic use of AAS, particularly with long-term or high-dose oral steroid exposure. The cysts form when blood sinusoids within the liver dilate, and the surrounding hepatocytes die. Peliosis hepatis is typically asymptomatic until a cyst ruptures, which can cause life-threatening intra-abdominal hemorrhage. While rare, documented cases in AAS users underscore the importance of hepatic monitoring and the risks of unsupervised long-duration use.

The most alarming hepatic complication of anabolic steroid use is hepatocellular carcinoma (HCC) — primary liver cancer. Although the absolute incidence of HCC attributable to AAS is low, case reports dating back to the 1970s have documented the development of liver tumors in patients receiving long-term AAS therapy, particularly with 17-alpha alkylated compounds. Some of these tumors have been reported to regress upon cessation of AAS use, suggesting a hormone-dependent mechanism rather than classical carcinogenesis, but others have pursued a malignant course. The molecular mechanisms likely involve androgen receptor-mediated promotion of hepatocyte proliferation and impairment of normal apoptotic processes.

Hormonal and Reproductive Consequences

The endocrine consequences of exogenous anabolic steroid use are among the most predictable and physiologically fundamental of all its effects. The hypothalamic-pituitary-gonadal (HPG) axis — the hormonal feedback system that regulates natural testosterone production — is exquisitely sensitive to circulating androgen levels. When supraphysiologic amounts of synthetic androgens enter the bloodstream, the hypothalamus decreases its secretion of gonadotropin-releasing hormone (GnRH), and the pituitary gland reduces its production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Without adequate LH signaling, the Leydig cells of the testes cease producing testosterone. Without FSH, spermatogenesis — the production of sperm — is severely impaired or halted entirely.

Testicular atrophy is a direct and predictable consequence of HPG axis suppression. With prolonged absence of LH stimulation, the Leydig cells undergo atrophy, and the testicles themselves decrease measurably in size and volume — a change that many users notice within weeks of beginning a cycle and that correlates directly with the degree of gonadotropin suppression. Testicular atrophy is generally reversible upon cessation of AAS use, but recovery of testicular volume and natural testosterone production can take months to years and may be incomplete in cases of particularly heavy or prolonged use, especially when recovery is not medically supported.

Male infertility associated with AAS use has become an increasingly recognized clinical problem. Since spermatogenesis depends on both FSH stimulation and locally high intratesticular testosterone concentrations — concentrations that are paradoxically suppressed during exogenous AAS use despite elevated systemic testosterone — sperm production is markedly impaired during cycles. Sperm count, motility, and morphology are all adversely affected. Recovery of sperm parameters after AAS cessation follows a timeline similar to that of testosterone recovery, typically 3–12 months, but a proportion of heavy long-term users experience prolonged or permanent azoospermia (absence of sperm). Men planning to have children should be explicitly counseled about this risk before initiating AAS use.

Gynecomastia — the development of glandular breast tissue in men — is another endocrine consequence of AAS use and one of the most psychologically distressing for many affected users. It arises because testosterone and certain other AAS undergo aromatization, a metabolic process catalyzed by the enzyme aromatase, which converts androgens into estrogens. Elevated circulating estrogen in men stimulates estrogen receptors in breast tissue, leading to glandular proliferation. The amount of estrogen produced depends on the total androgen load, individual variability in aromatase activity, and body fat percentage (aromatase is highly active in adipose tissue). Mild gynecomastia may be reversible with treatment; established glandular tissue typically requires surgical removal.

In women who use anabolic steroids — a growing demographic — virilization represents the most clinically significant hormonal consequence. Supraphysiologic androgen exposure drives the development of male secondary sex characteristics in female users, including clitoral enlargement, deepening of the voice (due to laryngeal growth), facial and body hair growth, and male-pattern scalp hair loss. Some of these changes — particularly voice deepening and clitoral growth — may be permanent even after cessation of AAS use. Menstrual irregularities or complete cessation of menstruation (amenorrhea) are common and reflect disruption of the female HPG axis by elevated androgen levels. These effects are dose- and duration-dependent.

Psychological and Mental Health Effects

The psychological effects of anabolic steroids are multifaceted and have been the subject of significant scientific investigation and public debate, often colored by media-driven narratives of “roid rage” that both oversimplify and, in some cases, obscure genuine clinical concerns. A comprehensive understanding of the psychological dimension of AAS use must account for several distinct phenomena: the acute mood effects during active use, the psychological consequences of AAS-induced hormonal changes, the relationship between AAS and aggression, the mental health burden of AAS dependence, and the emerging evidence on structural and functional brain changes with long-term use.

Randomized, double-blind, placebo-controlled studies examining the psychological effects of supraphysiologic testosterone doses in healthy men have consistently demonstrated increases in measures of hostility, irritability, and aggressiveness, particularly in individuals with pre-existing tendencies toward aggression. A landmark study by Pope and Katz, published in the Archives of General Psychiatry, documented psychiatric symptoms including hypomania, major depression, and aggressive behavior in a significant proportion of AAS users. However, the prevalence of severe violent behavior attributable directly and exclusively to AAS use — the popular conception of “roid rage” — appears to be lower than sensationalized media accounts suggest. The most severe behavioral disturbances are most common in individuals with predisposing factors such as a personal or family history of mood disorders or impulsive behavior.

Depression and anxiety are particularly prevalent during the “off-cycle” and post-cycle phases of AAS use, reflecting the physiological consequences of HPG axis suppression. When AAS use ceases, natural testosterone production is often severely suppressed for weeks or months, during which time the individual may experience profoundly low testosterone levels. Clinical hypogonadism — even temporary — is associated with anhedonia (inability to feel pleasure), fatigue, loss of libido, and significant depressive symptoms. This post-cycle depression can be severe enough to drive users back to AAS use before allowing recovery, a pattern that contributes directly to the development of psychological dependence.

Muscle dysmorphia — sometimes called “reverse anorexia” or “bigorexia” — is a body image disorder characterized by the persistent belief that one’s body is insufficiently large or muscular, even when objective measurement indicates substantial muscle mass. This condition, which shares features with body dysmorphic disorder and may be classified within the obsessive-compulsive spectrum, has been linked to AAS use in multiple directions: muscle dysmorphia can predispose individuals to AAS use as a means of addressing perceived inadequacy, while the body composition changes achieved with AAS use and the mood effects during cessation can reinforce and entrench dysmorphic thinking. Rates of muscle dysmorphia are substantially higher in non-medical AAS users than in the general population or in non-using gym-goers.

Long-term structural changes in the brain have been documented in MRI studies of long-term AAS users. Specific areas implicated include the amygdala and striatum — regions associated with emotional regulation and reward processing — which show both volumetric differences and altered functional connectivity in heavy AAS users compared to non-using controls. Whether these changes represent direct neurological effects of the drugs, consequences of the associated hormonal dysregulation, or pre-existing differences in individuals prone to AAS use remains an active area of investigation. Animal studies using rodent models have demonstrated AAS-induced changes in dopaminergic and serotonergic neurotransmission, providing mechanistic plausibility for the observed human findings.

Effects on Specific Populations

Adolescents represent the population at greatest risk from anabolic steroid use. The developing body is uniquely vulnerable in ways that differ fundamentally from adult risks. The most significant concern specific to adolescents is premature epiphyseal closure — the early sealing of the growth plates in long bones. Normally, growth plates remain open until the mid-to-late teenage years, during which time they are responsible for longitudinal bone growth. Exogenous androgen exposure accelerates the maturation and eventual closure of these growth plates, potentially causing a permanent reduction in final adult height. Studies have documented final heights below predicted genetic potential in adolescent AAS users, with the degree of growth restriction correlating with age at first use and total duration of exposure.

In addition to growth effects, adolescent AAS use is associated with more pronounced hormonal disruption than occurs in adults, reflecting the ongoing development of the HPG axis during puberty. Premature HPG axis activation or disruption can interfere with the natural hormonal orchestration of adolescent development, with consequences for reproductive and sexual health that extend into adult life. Psychologically, adolescents are also more susceptible to the mood-altering effects of androgens and to the development of muscle dysmorphia and body image disorders, given the well-documented vulnerability of the adolescent brain to substance use and the particular sensitivity of this developmental period to social pressures around body appearance.

For women, anabolic steroid use introduces risks not experienced by male users, centered on the profound androgenic stimulation of tissues that are developed to respond to estrogen. Beyond the virilizing effects described in the hormonal section, women using AAS face risks of polycystic ovarian morphology, impaired fertility, and the permanent physical changes associated with prolonged androgen exposure. Ironically, the same performance-enhancing effects that make AAS attractive to female athletes carry a far less favorable risk-benefit profile for women than for men, because the naturally lower testosterone baseline in women means that even moderate doses of exogenous AAS represent much larger multiples of the normal physiological level.

Older adult men represent a growing demographic of AAS users, often seeking the perceived anti-aging or body composition benefits of testosterone supplementation without a formal medical diagnosis of hypogonadism. In this population, the cardiovascular risks of supraphysiologic androgen exposure are compounded by pre-existing age-related cardiovascular risk factors such as hypertension, dyslipidemia, and reduced arterial elasticity. The hematocrit-elevating effects of AAS are particularly concerning in older men, in whom elevated red blood cell counts substantially increase the risk of thrombotic events. Prostate health is another critical concern: while evidence does not support the notion that TRT at physiological doses causes prostate cancer, supraphysiologic androgen exposure could stimulate growth of subclinical or pre-existing prostate lesions.

Legal Status and Regulatory Framework

In the United States, anabolic steroids are classified as Schedule III controlled substances under the Controlled Substances Act, as established by the Anabolic Steroid Control Act of 1990 and subsequently expanded by the Designer Anabolic Steroid Control Act of 2014. The Schedule III designation reflects a determination by Congress and the Drug Enforcement Administration (DEA) that AAS have accepted medical uses in the United States and a moderate potential for physical and psychological dependence. Possession of AAS without a valid prescription is a federal offense that can result in up to one year in prison for a first offense; trafficking carries penalties of up to five years. Possession with intent to distribute carries sentences up to 10 years, enhanced by prior convictions.

The international legal landscape for anabolic steroids is heterogeneous. In many European countries, including the United Kingdom, Canada, and Australia, possession of AAS for personal use is treated differently from distribution: personal possession may be decriminalized or carry only minor penalties, while distribution remains a criminal offense. In some countries — most notably Mexico and several South American and Eastern European nations — AAS are available over-the-counter without a prescription, a fact that has historically made these jurisdictions attractive for “steroid tourism” and importation schemes. Importing AAS into the United States, even for personal use, is a violation of federal law regardless of the legal status at the origin country.

In the context of organized sport, the governance of AAS is administered separately from national criminal law through the World Anti-Doping Agency (WADA) and its implementing bodies — national anti-doping organizations (NADOs) and international federations. WADA’s Prohibited List, updated annually, includes all anabolic agents, including both endogenous steroids (like natural testosterone, which can be detected via isotope ratio mass spectrometry) and exogenous synthetic AAS. Anti-doping rule violations carry sanctions up to four years for a first offense of intentional doping, with bans for life possible for repeat violations. The regulatory infrastructure around anti-doping is separate from and operates in parallel with criminal law enforcement.

Detection and Anti-Doping Testing

The detection of anabolic steroid use in anti-doping and forensic contexts relies on a suite of sophisticated analytical techniques, primarily applied to urine samples collected under strict chain-of-custody protocols. Standard initial screening uses immunoassay techniques, which provide rapid, cost-effective results but require confirmation. Confirmatory analysis employs gas chromatography-mass spectrometry (GC-MS) and, increasingly, liquid chromatography-tandem mass spectrometry (LC-MS/MS), which can identify the specific chemical identity of a steroid metabolite with very high sensitivity and specificity. These methods can detect nanogram-per-milliliter quantities of steroid metabolites in urine and are capable of identifying a compound weeks or months after its last administration, depending on the compound and the dose used.

Detection windows vary substantially between different AAS compounds and are a major determinant of their use patterns in competitive sport. Short-acting compounds with rapid metabolism, such as testosterone propionate or the oral stanozolol, may have detection windows of only days to a few weeks for their primary metabolites. Long-acting injectable esters and nandrolone decanoate have detection windows of several months for characteristic metabolites. Notably, the long-acting nandrolone metabolite 19-norandrosterone can remain detectable for up to 18 months or longer in some individuals. The Athlete Biological Passport (ABP), introduced by WADA in 2008, represents a longitudinal approach to anti-doping that tracks an athlete’s biomarker profile over time — including haemoglobin, haematocrit, and reticulocyte percentage — to detect indirect evidence of doping without relying on the direct detection of specific compounds.

The detection of endogenous testosterone manipulation is particularly challenging because normal individuals produce testosterone naturally. The standard approach uses the testosterone-to-epitestosterone (T/E) ratio, normally maintained within a predictable physiological range. A T/E ratio above 4:1 (the WADA threshold) triggers further investigation. When elevated T/E ratios are found, carbon isotope ratio analysis (GC-IRMS) is employed to determine whether the detected testosterone is of synthetic (exogenous) origin, based on differences in the ratio of carbon-13 to carbon-12 between synthetic and naturally produced testosterone. This technique, which exploits the slightly different carbon isotope signatures of synthetic and biological compounds, has been used to catch athletes even when T/E ratios were within the nominally acceptable range.

Dependence, Addiction, and Pathways to Treatment

Anabolic steroid dependence is a clinically recognized condition in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) under “other hallucinogen use disorder” — more accurately reflected in the ICD-10 as “anabolic steroid dependence.” Research by Dr. Harrison Pope and colleagues at Harvard Medical School, among other investigators, has characterized the phenomenon in detail. Dependence can be physical and psychological. Physical dependence reflects the body’s adaptation to chronic exogenous androgen exposure — specifically, the suppression of endogenous testosterone production — such that cessation of AAS use precipitates a physiological withdrawal syndrome. Psychological dependence is rooted in the powerful behavioral reinforcement of the muscle-building and mood-enhancing effects of AAS.

The withdrawal syndrome associated with AAS cessation is primarily characterized by hypogonadal symptoms resulting from the suppressed natural testosterone system. These symptoms include severe fatigue, profound depression, decreased libido, cognitive dulling, loss of muscle mass and strength, and sleep disturbances. In severe cases, steroid withdrawal depression can be clinically indistinguishable from major depressive disorder and carries a non-trivial risk of suicidal ideation, as documented in case reports and survey studies. The severity and duration of withdrawal symptoms correlate with the total prior AAS exposure — heavier and more prolonged use is associated with more severe and longer-lasting symptoms, potentially persisting for 6–18 months without medical intervention.

Medical treatment of AAS dependence and post-cycle recovery typically involves strategies to accelerate restoration of the HPG axis. Human chorionic gonadotropin (hCG), which mimics LH signaling, is administered to stimulate Leydig cell recovery and restore intratesticular testosterone production. Selective estrogen receptor modulators (SERMs) — tamoxifen (Nolvadex) and clomiphene citrate (Clomid) — are used to block estrogenic feedback at the hypothalamic and pituitary level, stimulating the release of GnRH, LH, and FSH and thereby driving natural testosterone recovery. These protocols, collectively referred to in non-medical circles as “post-cycle therapy” (PCT), are derived from fertility medicine but are now incorporated into evidence-based treatment guidelines for AAS dependence, though most of the supporting literature consists of case series and expert consensus rather than large randomized trials.

Psychotherapeutic interventions are an essential complement to medical management. Cognitive-behavioral therapy (CBT) approaches adapted for body image disorders and muscle dysmorphia have shown promise in addressing the underlying psychological drivers of AAS use and in preventing relapse. Motivational interviewing techniques are particularly valuable given that many individuals presenting for treatment have ambivalent attitudes toward cessation, having organized significant aspects of their social identity, self-esteem, and lifestyle around AAS use and bodybuilding. Peer support groups and, increasingly, online harm-reduction communities staffed by healthcare professionals serve as accessible resources for individuals not yet ready to engage with formal treatment services. The clinical management of AAS dependence is a developing subspecialty within addiction medicine and sports medicine, with evolving guidelines as the evidence base grows.

Conclusion: Steroids in Context

Anabolic steroids occupy a paradoxical position in modern medicine and public health: they are genuinely valuable therapeutic agents when used appropriately under medical supervision for verified clinical indications, and simultaneously they represent a serious public health concern when used non-medically at supraphysiologic doses for performance enhancement or aesthetic purposes. The evidence reviewed in this guide supports a nuanced view that rejects both the sensationalized demonization of all steroid use and the reckless minimization of documented health risks that is common in certain fitness and bodybuilding circles.

The medical literature on the risks of non-medical AAS use is extensive, consistent, and compelling. Cardiovascular damage — particularly adverse cardiac remodeling, dyslipidemia, and increased thrombotic risk — represents the most serious long-term health consequence and accounts for the elevated cardiovascular mortality documented in long-term AAS users. Hormonal disruption, hepatotoxicity, and psychological effects, including dependence, are clinically significant additional concerns. These risks are not hypothetical: they are documented in peer-reviewed literature from multiple countries and multiple decades of investigation. They apply to recreational users, not just elite athletes.

For individuals who are using or considering using anabolic steroids for non-medical purposes, the most important step is honest engagement with the medical system. Physicians are increasingly experienced with and non-judgmental toward patients presenting with concerns about AAS use. Blood work to assess cardiovascular risk markers, liver function, and hormonal parameters can provide a meaningful picture of an individual’s current health status and facilitate early identification of emerging problems. For those experiencing difficulty ceasing AAS use, evidence-based treatment is available. The key takeaway of this guide is not a simple condemnation or endorsement, but rather the conviction that accurate, complete information is the foundation of any genuinely health-protective decision.